The general aim of the proposed research is to investigate the influence of disease on the relationship between the concentration and intensity of pharmacologic effects of drugs. The studies will be designed to differentiate between the direct effects of diseases on the biophasic drug concentration-pharmacologic response relationship (which will be of primary interest) on the one hand, and indirect (and therefore potentially confounding) effects on the other. The indirect effects, which will be either excluded or accounted for in our research strategy, include pharmacokinetic perturbations such as disease-induced changes in protein binding, distribution, metabolism and excretion, formation and elimination of active metabolites, drug-drug metabolite interactions, and differential pharmacologic activities of individual enantiomers. We will use animal models of disease, specifically rats with experimental renal failure, hepatic dysfunction diabetes, thyroid dysfunction, hyperpyrexia, and arthritis. We will also investigate the effects of certain nonpathologic changes in physiologic status, particularly pregnancy and possibly obesity. The drugs to be studied represent examples of CNS depressants (phenobarbital), anticonvulsants (phenytoin), analgesics (acetaminophen), and antihypertensives (clonidine). The pharmacologic effects to be measured include onset of loss of righting reflex, protection from seizures, analgesia, and changes of blood pressure. Two different experimental models of each disease will be utilized to distinguish effects referable to a particular method of inducing the disease from effects characteristic of the disease itself. The roles of potentially active or interactive metabolites will be assessed directy. The longer term objective of this research is to address a question that is central to the individualized optimization of patients' drug therapy: will certain diseases or other alterations of physiologic status modify not only the pharmacokinetics but also (and perhaps predominantly) the pharmacodynamics (concentration-effect relationship) of a drug?

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM042850-04
Application #
3301776
Study Section
Special Emphasis Panel (SRC (02))
Project Start
1989-01-01
Project End
1993-12-31
Budget Start
1992-01-01
Budget End
1992-12-31
Support Year
4
Fiscal Year
1992
Total Cost
Indirect Cost
Name
State University of New York at Buffalo
Department
Type
Schools of Pharmacy
DUNS #
038633251
City
Buffalo
State
NY
Country
United States
Zip Code
14260
Fung, H L; Booth, B P; Tabrizi-Fard, M (1999) Therapeutics of nitric oxide modulation. Met Ions Biol Syst 36:723-49
Booth, B P; Fung, H L (1998) Contribution of vascular tissue to the antiplatelet activity of sodium nitroprusside. J Cardiovasc Pharmacol 32:129-33
Booth, B P; Nolan, T D; Fung, H L (1997) Nitroglycerin-inhibited whole blood aggregation is partially mediated by calcitonin gene-related peptide -- a neurogenic mechanism. Br J Pharmacol 122:577-83
Bauer, J A; Nolan, T; Fung, H L (1997) Vascular and hemodynamic differences between organic nitrates and nitrites. J Pharmacol Exp Ther 280:326-31
Bauer, J A; Balthasar, J P; Fung, H L (1997) Application of pharmacodynamic modeling for designing time-variant dosing regimens to overcome nitroglycerin tolerance in experimental heart failure. Pharm Res 14:1140-5
Booth, B P; Jacob, S; Bauer, J A et al. (1996) Sustained antiplatelet properties of nitroglycerin during hemodynamic tolerance in rats. J Cardiovasc Pharmacol 28:432-8
Bauer, J A; Booth, B P; Fung, H L (1995) Nitric oxide donors: biochemical pharmacology and therapeutics. Adv Pharmacol 34:361-81
Bangalore, R; Triggle, D J (1995) Age-dependent changes in voltage-gated calcium channels and ATP-dependent potassium channels in Fischer 344 rats. Gen Pharmacol 26:1237-42
Liu, J; Bangalore, R; Rutledge, A et al. (1994) Modulation of L-type Ca2+ channels in clonal rat pituitary cells by membrane depolarization. Mol Pharmacol 45:1198-206
Bachert, E L; Li, Z W; Zhao, L et al. (1994) A modified product inhibition model describes the nonlinear pharmacokinetics of nicorandil in rats. Pharm Res 11:1190-8

Showing the most recent 10 out of 48 publications